Abstract
Aggregation and fibril formation of amyloid-beta (Abeta) peptides Abeta40 and Abeta42 are central events in the pathogenesis of Alzheimer disease. Previous studies have established the ratio of Abeta40 to Abeta42 as an important factor in determining the fibrillogenesis, toxicity, and pathological distribution of Abeta. To better understand the molecular basis underlying the pathologic consequences associated with alterations in the ratio of Abeta40 to Abeta42, we probed the concentration- and ratio-dependent interactions between well defined states of the two peptides at different stages of aggregation along the amyloid formation pathway. We report that monomeric Abeta40 alters the kinetic stability, solubility, and morphological properties of Abeta42 aggregates and prevents their conversion into mature fibrils. Abeta40, at approximately equimolar ratios (Abeta40/Abeta42 approximately 0.5-1), inhibits (> 50%) fibril formation by monomeric Abeta42, whereas inhibition of protofibrillar Abeta42 fibrillogenesis is achieved at lower, substoichiometric ratios (Abeta40/Abeta42 approximately 0.1). The inhibitory effect of Abeta40 on Abeta42 fibrillogenesis is reversed by the introduction of excess Abeta42 monomer. Additionally, monomeric Abeta42 and Abeta40 are constantly recycled and compete for binding to the ends of protofibrillar and fibrillar Abeta aggregates. Whereas the fibrillogenesis of both monomeric species can be seeded by fibrils composed of either peptide, Abeta42 protofibrils selectively seed the fibrillogenesis of monomeric Abeta42 but not monomeric Abeta40. Finally, we also show that the amyloidogenic propensities of different individual and mixed Abeta species correlates with their relative neuronal toxicities. These findings, which highlight specific points in the amyloid peptide equilibrium that are highly sensitive to the ratio of Abeta40 to Abeta42, carry important implications for the pathogenesis and current therapeutic strategies of Alzheimer disease.
Highlights
(A)2 proteins in the form of diffuse and neuritic plaques in regions of the brain that are affected by the disease [1,2,3,4]
Potential interactions between A40 and A42 have been investigated previously by various research groups. These studies have shown that A40 can inhibit the aggregation and fibril formation of A42 [38, 41] and protect cultured neurons from A-induced neurotoxicity [40]
Unlike previous studies suggesting that A40 blocks the aggregation of monomeric A42 [41], our results show that A40 does not prevent further aggregation of the various A42 quaternary structures
Summary
(A) proteins in the form of diffuse and neuritic plaques in regions of the brain that are affected by the disease [1,2,3,4]. Animal models and in vitro cell culture studies have shown that, in most instances, FAD mutations enhance total A production, promote its aggregation and brain deposition, and/or alter the A40/A42 ratio in favor of A42 production (28 –30). To evaluate the consequences of altering the ratio A40/A42, several groups have investigated the effect of co-expressing the two A variants (A40 and A42) or altering the expression level of one or the other variant in cellular and animal models of AD These studies and other studies in human patients demon-. We determined the preferential effect of A40 on the kinetic stability, solubility, and fibrillogenesis rate of specific aggregation states of A42, including monomers, protofibrils, and fibrils. We explored the dynamics of exchange between monomeric A40 and A42 at the end of protofibrils and fibrils formed by each peptide and determined the effect of these interactions on the aggregate growth and morphology in vitro. The implications of these findings for intervention strategies for AD are discussed
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have